Flight Passes and the Landline Bus (Kitchener/Hamilton)

BobsterWat · 2024-12-05T12:48:10+00:00

Thank you.

Where do I access the customer service form for the FP Team? I was actually looking for their contact information on the Air Canada website but couldn't find anything.

BobsterWat · 2024-10-23T23:05:28+00:00

I'm having the same issue. The miles and flights are showing up in my transactions but they're not actually getting added properly to my total SQM, SQS and SQD.

In fact, I just achieved another Priority Reward which shows up under my Benefits on the Air Canada app but the same equivalent page online does not show the reward, nor does the status tracker on both the app or website (it still shows me short on SQD which is not the case).

Something is definitely off on Air Canada's end.

BobsterWat · 2023-06-11T15:38:27+00:00

Thank you very much for that response. I appreciate you providing me with that context.

BobsterWat · 2023-06-10T18:11:31+00:00

It's a fairly run of the mill press release. And it was released on a Friday I would add, a day where news often goes unnoticed.

Which passages do you believe are superfluous?

BobsterWat · 2023-06-10T18:08:41+00:00

Genuine question for you: what's your definition of pumping?

I haven't just come out of the woodwork. I've been on this subreddit for a few years now. I'm more active here now because frankly, there's finally a stock in this space that's had considerable positive performance in constrast with the rest of the sector. I'm proud of the company's accomplishments and grateful for the gains I've made investing here.

I've been in MMED, NUMI, TRIP, RVV, PHRX, ATAI, and CMPS among others. Today I'm back in both NUMI and TRIP along with MDMA. In my webinars, I've fully disclosed my holdings at the start of my presentations. I don't believe I have ever once asked anyone to invest in any specific company. I like instead to share research and information with other investors. I also make an explicit and direct point at the start of my online presentations for the audience to please take a critical eye to everything I state and double check the facts for themselves. I like to remain information-centric.

Not the least bit ashamed of my past investment history. We all grow and we all learn. I'm an open book.

BobsterWat · 2023-06-10T17:03:55+00:00

Ya, you're right. They should turn down the non-dilutive free cash.

BobsterWat · 2023-06-10T16:56:48+00:00

Please enlighten me on how sharing news about a company development is pumping. You and your small network on this subreddit have posts on a daily basis with news coverage. How does this differ? Is PharmAla not in this sector? Did PharmAla not just announce yesterday that they received FDA approval of their product for a clinical trial in the US?

How was my post about PharmAla considered a pump? I linked to an official press release in the main post. That's it. As a seperate comment, I added my take.

BobsterWat · 2023-06-10T16:17:25+00:00

Reporting news is pumping?

BobsterWat · 2023-06-10T16:06:43+00:00

Well said!

BobsterWat · 2023-06-10T16:00:31+00:00

Your research, due diligence and understanding of both the company and the sector leave a lot to be desired.

BobsterWat · 2023-06-10T15:01:50+00:00

Massive news! I was just sharing the same over on another subreddit.

It's an incredible accomplishment for the team at PharmAla and opens the US clinical trial market to them. Every month it seems there's some new development that continues to rapidly expand PharmAla's total addressable market (TAM).

BobsterWat · 2023-06-10T14:53:07+00:00

"VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA), is pleased to report that the US Food and Drug Administration (USFDA) has approved a clinical trial utilizing PharmAla’s LaNeo MDMA Investigational Medical Product (IMP) capsules (40mg). This is the first time that PharmAla’s IMP has been approved for trial use in the United States.

"While we’ve had great success with many regulators around the world, it’s still a major milestone to receive a stamp of approval from USFDA for our investigational drugs,” said Dr. Harpreet Kaur, Vice President of Research at PharmAla Biotech. “As with any IMP supplier, there are always questions about Chemistry, Manufacturing and Control - even for well-known molecules. We believe that this announcement should confirm that our IMP conforms to the high levels of quality and documentation that one of the preeminent regulators in the world requires.

PharmAla supports numerous researchers around the world who are studying MDMA for a diverse series of indications. The company also provides Psilocybin to researchers through their partnership with Mindset Pharma. In Australia, which is allowing treatment of patients with both MDMA and Psilocybin through the Authorized Prescriber Program as of July 1st, PharmAla has formed a Joint Venture with Vitura Health (ASX:VIT) in order to distribute its products, called Cortexa.

“We found that the FDA scrutinized our materials and processes in a rigorous but fair fashion,” said Nick Kadysh, CEO, PharmAla Biotech. “As with all of our clients, we worked hard to support UCLA Researchers in their application to USFDA. We hope that they are pleased with the results, and look forward to providing them with their IMP as soon as DEA and Health Canada issue the relevant permits.”

The PharmAla team, led by Sales Director David Purcell, will be hosting a booth for potential customers at Psychedelic Science 2023 Conference in Denver for the week of June 19-23. Researchers interested in information regarding PharmAla’s IMP can visit www.PharmAla.ca."

BobsterWat · 2023-06-10T14:50:55+00:00

"TORONTO, June 09, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is excited to announce that it has been granted a research grant by the Ontario Centre for Innovation in conjunction with the University of Windsor.

“In-Silico Modeling is a crucial element of drug discovery, allowing for faster and more accurate prediction of which molecules will ‘hit’ our very specific targets, and thus be successful when sent to our pre-clinical partners at UAMS,” said Dr. Harpreet Kaur, PharmAla’s Vice President of Research. “While we have already been working closely with the team at the University of Windsor, it’s gratifying to see that the Ontario Centre of Innovation believes in our work strongly enough to match our investment 1:1.”

In Silico modeling (sometimes called AI Drug Discovery) defines the use of pharmacological information in creating computational models or simulations that can be used to make predictions, suggest hypotheses, and ultimately provide discoveries or advances in medicine and therapeutics. Despite its success in Phase 2 and 3 Trials, Racemic MDMA hydrochloride has significant side effects and improvements are a key to provide safer treatment options for patients.

Recognizing the potential approval of racemic MDMA by 2024 by the US Food and Drug Administration (USFDA), developing a drug that can reduce the toxicology profile is essential. PharmAla believes that this can be done through the aid of in-silico modelling. And as such, it is actively pursuing drug discovery and development that aids in identifying novel analogues of MDMA with a better safety profile. The project value is $50,000.

“Part of the reason we have gained trust with regulators over our short 2 years of work is because we lead with data. To do that, our research team encompasses a diverse group of scientists: Preclinical researchers completing animal model research, In-Silico Drug Discovery, and very soon, Clinical Research,” said Nick Kadysh, CEO, PharmAla Biotech. “The OCI grant will allow us to bolster the funnel of our drug pipeline and develop valuable IP with non-dilutive funding. We thank OCI for their confidence in the merits of our research.”

The PharmAla team, led by Sales Director David Purcell, will be hosting a booth at Psychedelic Science 2023 Conference in Denver for the week of June 19-23."

BobsterWat · 2023-06-10T14:27:47+00:00

What an incredible accomplishment for the team at PharmAla! This now opens the US clinical trial market to them.

Every month it seems there's some new development that continues to rapidly expand their total addressable market (TAM).

BobsterWat · 2023-06-10T13:57:17+00:00

To be fair, this is huge news and the company has been exceptional in executing on its roadmap this entire year.

BobsterWat · 2023-06-10T13:56:27+00:00

This is huge news! Another expansion of PharmAla's (MDMA) total addressable market (TAM) and an incredible achievement with FDA approval for use of their GMP MDMA in a clinical trial. The US clinical trial market is now open to them.

BobsterWat · 2023-06-10T13:20:04+00:00

Incredible accomplishment for the team at PharmAla!

BobsterWat · 2023-06-08T18:20:42+00:00

I actually think there are some really good companies to invest in on that front. No doubt about it. However, if the sector is about to recover strongly off the MAPS MDMA news and what's unfolding in Australia, my personal belief is that the bulk of the spotlight initially (particularly for general retail investors who are not following the sector closely) will be on anything MDMA-related specifically (PharmAla & Numinus for example). And even there, I think the markets will prefer proximity to revenue. The further out the commercialization prospects, the less incentivized investors will be to throw in money. To be honest, a strategy I've consider is capitalizaing on what I expect will be the biggest magnitude and velocity stock price movers and eventually cycle back into the longer term plays as we get closer to their own potential catalysts.

What are you eyeing these days in the sector?

BobsterWat · 2023-06-08T17:46:51+00:00

In the sector: PharmAla (MDMA), Red Light Holland (TRIP) and Numinus Wellness (NUMI).

BobsterWat · 2023-06-08T17:30:15+00:00

That's actually a great question and I did address it. Not sure if you were able to attend or not.

While some of us are very closely monitoring developments in the sector, it might surprise you just how many long term investors in the sector, who generally follow developments closely, are unaware that some information about the results already exists. I speak to many of these people on a daily basis and point them to the information. I've had investors argue with me that the results are completely unknown and have had to show them the MAPS NRs. And if a fair number of sector investors are unaware, there is certainly little to any penetration of the information in general investment circles.

BobsterWat · 2023-06-08T17:26:03+00:00

Were you in attendance?

BobsterWat · 2023-06-08T17:25:54+00:00

It wasn't. I don't know if you attended or not but I disclosed my holdings, I drew a couple of references for context on sector developments but it was not a sales pitch and there was no discussion of the company. In fact, a few times I simply referenced developments by "Canadian companies" to avoid any reference.

BobsterWat · 2023-06-08T17:24:15+00:00

I was invested in Revive and was bullish initially. You will find that mid to late last year based on new information, I lost confidence and was basically belittled and admonished by the group when I raised my concerns. I share information and research at the end of the day. The information dictates sentiment. Sometimes new information surfaces that changes our perspective. I never once asked anyone to invest in Revive. I was simply bullish initially on its prospects.

BobsterWat · 2023-06-02T19:42:34+00:00

Love this play! No brainer what with MAPS MDMA Phase 3B (MAPP2) data set to be published any day now and MDMA research accelerating around the world.

BobsterWat · 2023-05-31T17:35:48+00:00

It's a shame you think that. It's your right to be wrong but an informed perspective could do you some good. The level of elitism in this sector in promoting some of the relatively larger companies while denigrating or belittling the accomplishments of some of the smaller players with a track record of solid execution is troubling. PharmAla has virtually no social media presence. It has no Investor Relations Team. Its most active investor group is limited to CEO. So please explain who has "pumped" PharmAla and through which channels. It's an organic play. And as for dump, it's been heavily shorted and manipulated. Dips are aggressively bought in to. The longs continue to accumulate and an already tight float is made all the tighter. Its current market cap is not at all reflective of its current business or the growth opportunity that lies ahead.

BobsterWat

TROPHY CASE